Unable to raise enough venture money for his Genome Corp. in the market conditions of the mid-80s, Dr. Gilbert was part of a new wave of genome startups in 1992, supported by venture capital, public stock offerings, or private corporate funds launched.
Unable to raise enough venture money for his Genome Corp. in the market conditions of the mid-80s, Dr. Gilbert was part of a new wave of genome startups in 1992 public stock offerings, or private corporate funds launched. A new wave of genome startups in 1992 was supported by venture capital.